The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2021-09-12
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate
the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant
tumors. The study will consist of a dose-escalation and dose-finding component to establish
the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and to evaluate the
preliminary antitumor activity of HX009.